Lv3
290 积分 2021-06-02 加入
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
2个月前
已完结
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
2个月前
已完结
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis
9个月前
已完结
Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis
11个月前
已关闭
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
1年前
已完结
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
1年前
已完结
Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation
1年前
已完结
Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study
1年前
已完结
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
1年前
已完结
Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis
1年前
已完结
皖公网安备34019202002308
